NasdaqGS:EXELBiotechs
A Look At Exelixis (EXEL) Valuation After Strong Q1 2026 Results And Zanzalintinib FDA Milestone
Why Exelixis stock is on investors’ radar after Q1 2026
Exelixis (EXEL) is back in focus after first quarter 2026 earnings, with revenue of US$610.81 million, net income of US$210.47 million, and FDA progress on zanzalintinib alongside active share repurchases.
See our latest analysis for Exelixis.
The stock has cooled slightly after earnings, with a 1 day share price decline of 5.11% to US$46.21. However, a 1 year total shareholder return of 26.60% and a 3 year total shareholder return of...